JP2017538671A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017538671A5 JP2017538671A5 JP2017521577A JP2017521577A JP2017538671A5 JP 2017538671 A5 JP2017538671 A5 JP 2017538671A5 JP 2017521577 A JP2017521577 A JP 2017521577A JP 2017521577 A JP2017521577 A JP 2017521577A JP 2017538671 A5 JP2017538671 A5 JP 2017538671A5
- Authority
- JP
- Japan
- Prior art keywords
- administration
- sdab
- pharmaceutical composition
- subject
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 7
- 238000002965 ELISA Methods 0.000 claims 6
- 241000124008 Mammalia Species 0.000 claims 6
- 238000003018 immunoassay Methods 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 229940126619 mouse monoclonal antibody Drugs 0.000 claims 6
- 229920001184 polypeptide Polymers 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 102100030708 GTPase KRas Human genes 0.000 claims 4
- 238000011200 topical administration Methods 0.000 claims 4
- 239000012491 analyte Substances 0.000 claims 3
- 238000003556 assay Methods 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 238000007918 intramuscular administration Methods 0.000 claims 3
- 238000004811 liquid chromatography Methods 0.000 claims 3
- 238000004949 mass spectrometry Methods 0.000 claims 3
- 239000007922 nasal spray Substances 0.000 claims 3
- 229940097496 nasal spray Drugs 0.000 claims 3
- 239000007921 spray Substances 0.000 claims 3
- 238000007920 subcutaneous administration Methods 0.000 claims 3
- 238000013518 transcription Methods 0.000 claims 3
- 230000035897 transcription Effects 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 239000003889 eye drop Substances 0.000 claims 2
- 229940012356 eye drops Drugs 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 238000007911 parenteral administration Methods 0.000 claims 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 claims 1
- 102000004495 STAT3 Transcription Factor Human genes 0.000 claims 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 claims 1
- 210000000170 cell membrane Anatomy 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 102200006539 rs121913529 Human genes 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019149269A JP6928773B2 (ja) | 2014-10-23 | 2019-08-16 | 細胞内抗原に対して指向された単一ドメイン抗体 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462067908P | 2014-10-23 | 2014-10-23 | |
| US62/067,908 | 2014-10-23 | ||
| US201562148656P | 2015-04-16 | 2015-04-16 | |
| US62/148,656 | 2015-04-16 | ||
| US201562188353P | 2015-07-02 | 2015-07-02 | |
| US62/188,353 | 2015-07-02 | ||
| US201562210795P | 2015-08-27 | 2015-08-27 | |
| US62/210,795 | 2015-08-27 | ||
| PCT/US2015/057223 WO2016065323A2 (en) | 2014-10-23 | 2015-10-23 | Single domain antibodies directed against intracellular antigens |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019062231A Division JP6670963B2 (ja) | 2014-10-23 | 2019-03-28 | 細胞内抗原に対して指向された単一ドメイン抗体 |
| JP2019149269A Division JP6928773B2 (ja) | 2014-10-23 | 2019-08-16 | 細胞内抗原に対して指向された単一ドメイン抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017538671A JP2017538671A (ja) | 2017-12-28 |
| JP2017538671A5 true JP2017538671A5 (OSRAM) | 2018-11-29 |
Family
ID=55761757
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017521577A Pending JP2017538671A (ja) | 2014-10-23 | 2015-10-23 | 細胞内抗原に対して指向された単一ドメイン抗体 |
| JP2019062231A Active JP6670963B2 (ja) | 2014-10-23 | 2019-03-28 | 細胞内抗原に対して指向された単一ドメイン抗体 |
| JP2019149269A Active JP6928773B2 (ja) | 2014-10-23 | 2019-08-16 | 細胞内抗原に対して指向された単一ドメイン抗体 |
| JP2021105631A Active JP6986180B2 (ja) | 2014-10-23 | 2021-06-25 | 細胞内抗原に対して指向された単一ドメイン抗体 |
| JP2021192139A Active JP7195400B2 (ja) | 2014-10-23 | 2021-11-26 | 細胞内抗原に対して指向された単一ドメイン抗体 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019062231A Active JP6670963B2 (ja) | 2014-10-23 | 2019-03-28 | 細胞内抗原に対して指向された単一ドメイン抗体 |
| JP2019149269A Active JP6928773B2 (ja) | 2014-10-23 | 2019-08-16 | 細胞内抗原に対して指向された単一ドメイン抗体 |
| JP2021105631A Active JP6986180B2 (ja) | 2014-10-23 | 2021-06-25 | 細胞内抗原に対して指向された単一ドメイン抗体 |
| JP2021192139A Active JP7195400B2 (ja) | 2014-10-23 | 2021-11-26 | 細胞内抗原に対して指向された単一ドメイン抗体 |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US9663570B2 (OSRAM) |
| EP (3) | EP4006052A1 (OSRAM) |
| JP (5) | JP2017538671A (OSRAM) |
| KR (4) | KR102207382B1 (OSRAM) |
| CN (2) | CN111848793B (OSRAM) |
| AU (4) | AU2015335600B2 (OSRAM) |
| BR (4) | BR122020006907B8 (OSRAM) |
| CA (3) | CA2962275C (OSRAM) |
| CY (2) | CY1122035T1 (OSRAM) |
| DK (2) | DK3590962T3 (OSRAM) |
| ES (2) | ES2731876T3 (OSRAM) |
| HR (2) | HRP20211889T1 (OSRAM) |
| HU (2) | HUE057605T2 (OSRAM) |
| IL (2) | IL289769B2 (OSRAM) |
| LT (2) | LT3590962T (OSRAM) |
| MX (2) | MX379450B (OSRAM) |
| PL (2) | PL3209685T3 (OSRAM) |
| PT (2) | PT3209685T (OSRAM) |
| RS (2) | RS59063B1 (OSRAM) |
| RU (1) | RU2017116710A (OSRAM) |
| SI (2) | SI3590962T1 (OSRAM) |
| SM (2) | SMT201900413T1 (OSRAM) |
| TW (1) | TWI664289B (OSRAM) |
| WO (1) | WO2016065323A2 (OSRAM) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3590962T3 (da) | 2014-10-23 | 2021-12-13 | Singh Molecular Medicine Llc | Enkeltdomæneantistoffer rettet mod intracellulære antigener |
| US20180072815A1 (en) | 2014-10-23 | 2018-03-15 | Singh Biotechnology, Llc | Single Domain Antibodies Directed Against Intracellular Antigens |
| US20170267784A1 (en) | 2014-10-23 | 2017-09-21 | Singh Molecular Medicine, Llc | Single domain antibodies directed against intracellular antigens |
| CN107438620A (zh) | 2015-03-31 | 2017-12-05 | 韦斯夸尔德有限公司 | 多肽 |
| WO2016156466A1 (en) | 2015-03-31 | 2016-10-06 | Vhsquared Limited | Peptide construct having a protease-cleavable linker |
| ES2913200T3 (es) | 2015-03-31 | 2022-06-01 | Sorriso Pharmaceuticals Inc | Polipéptidos |
| MX2018002586A (es) | 2015-09-01 | 2020-11-24 | First Wave Bio Inc | Composiciones para usarse en el tratamiento de afecciones asociadas a una repsuesta inflamatoria anómala. |
| TWI746473B (zh) | 2015-11-02 | 2021-11-21 | 美商辛分子醫藥有限公司 | 針對細胞內抗原之單域抗體 |
| EP3386549A4 (en) * | 2015-12-10 | 2019-08-07 | City of Hope | Cell penetrating cyanine-coupled antibodies |
| WO2018060453A1 (en) | 2016-09-30 | 2018-04-05 | Vhsquared Limited | Compositions |
| AU2018234810B2 (en) | 2017-03-15 | 2023-05-11 | Pandion Operations, Inc. | Targeted immunotolerance |
| US10676516B2 (en) | 2017-05-24 | 2020-06-09 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| TW201922780A (zh) | 2017-09-25 | 2019-06-16 | 美商健生生物科技公司 | 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法 |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| KR20190076354A (ko) * | 2017-12-22 | 2019-07-02 | 주식회사 로피바이오 | 세포 내 침투능을 갖는 항 stat3 이중특이 항체를 포함하는, 염증성 질환 치료용 약학적 조성물 |
| EP3730150A4 (en) | 2017-12-22 | 2021-10-06 | Rophibio, Inc. | ANTI-STAT3 BISPECIFIC ANTIBODY WITH CELL-PENETRATING ABILITY AND THIS PHARMACEUTICAL COMPOSITION |
| US20210123061A1 (en) * | 2018-05-04 | 2021-04-29 | The Brigham And Women's Hospital, Inc. | Methods and compositions for treating inflammatory disease or disorder |
| KR102101561B1 (ko) * | 2018-07-25 | 2020-04-20 | 가톨릭대학교 산학협력단 | 신생혈관 표적용 조영제 조성물 및 이의 제조방법 |
| WO2020236875A1 (en) | 2019-05-20 | 2020-11-26 | Pandion Therapeutics, Inc. | Madcam targeted immunotolerance |
| CN114514243B (zh) | 2019-06-21 | 2025-01-24 | 索瑞索制药公司 | 多肽 |
| WO2020254827A1 (en) | 2019-06-21 | 2020-12-24 | Vhsquared Limited | Polypeptides |
| CN110357965A (zh) * | 2019-06-24 | 2019-10-22 | 浙江大学 | 一种突变型kras特异性抗体及其制备方法 |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| CN115485289A (zh) | 2020-03-11 | 2022-12-16 | 宾夕法尼亚大学董事会 | 使用工程化的病毒颗粒进行基因递送的方法和组合物 |
| US10980756B1 (en) | 2020-03-16 | 2021-04-20 | First Wave Bio, Inc. | Methods of treatment |
| CN115215939B (zh) * | 2021-04-14 | 2025-09-23 | 中山大学 | 一种融合蛋白及其制备方法与应用 |
| MX2024000309A (es) * | 2021-07-07 | 2024-04-09 | Singh Biotechnology Llc | Supresión de la uveítis mediante anticuerpos de dominio único. |
| JP2024534833A (ja) * | 2021-08-27 | 2024-09-26 | シン バイオテクノロジー、エルエルシー | 治療用単一ドメイン抗体 |
| IL313473A (en) | 2021-12-15 | 2024-08-01 | Interius Biotherapeutics Inc | Pseudotyped viral particles, compositions comprising the same, and uses thereof |
| WO2024003873A1 (en) * | 2022-06-30 | 2024-01-04 | Intrexon Actobiotics Nv D/B/A Precigen Actobio | Single variable domain antibodies against tumor necrosis factor-alpha |
| TW202409288A (zh) | 2022-07-25 | 2024-03-01 | 美商英特瑞斯生物療法公司 | 突變多肽、包含該等突變多肽之組合物及其用途 |
| TW202444412A (zh) | 2023-02-04 | 2024-11-16 | 美商默門塔醫藥公司 | 用於治療胎兒及新生兒溶血性疾病之組成物及方法 |
| WO2025004683A1 (ja) * | 2023-06-30 | 2025-01-02 | 国立大学法人大阪大学 | がん検査方法及びがん治療剤 |
| WO2025027511A1 (en) | 2023-07-30 | 2025-02-06 | Janssen Biotech, Inc. | Molecules that bind to mutant calreticulin and uses thereof |
| TW202527982A (zh) | 2023-09-11 | 2025-07-16 | 美商默門塔醫藥公司 | Fcrn抗體之醫藥組成物 |
| WO2025099576A1 (en) | 2023-11-06 | 2025-05-15 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating rheumatoid arthritis |
| US20250376509A1 (en) | 2023-11-21 | 2025-12-11 | Janssen Biotech, Inc. | Methods for treatment of myeloproliferative neoplasms |
| WO2025163617A1 (en) | 2024-02-04 | 2025-08-07 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating sjögren's disease |
| WO2025186787A1 (en) | 2024-03-08 | 2025-09-12 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating fetal and neonatal alloimmune thrombocytopenia |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| DE69334095T2 (de) * | 1992-07-17 | 2007-04-12 | Dana-Farber Cancer Institute, Boston | Verfahren zur intrazellulären Bindung von zielgerichteten Molekülen |
| FR2706486B1 (fr) * | 1993-06-16 | 1995-09-01 | Rhone Poulenc Rorer Sa | Séquences nucléiques, vecteurs les contenant, compositions pharmaceutiques et utilisations thérapeutiques. |
| JP2003531570A (ja) | 1999-07-27 | 2003-10-28 | アブジェニックス インク． | 神経障害に関連したポリペプチド蓄積を阻害する方法および組成物 |
| US6277974B1 (en) * | 1999-12-14 | 2001-08-21 | Cogent Neuroscience, Inc. | Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death |
| DE10019157A1 (de) | 2000-04-18 | 2001-11-15 | Stefan Duebel | Verfahren zum Einbringen von Liganden in lebende Zellen |
| EP1328626B1 (en) | 2000-05-26 | 2013-04-17 | National Research Council Of Canada | Single-domain brain-targeting antibody fragments derived from llama antibodies |
| US20040052762A1 (en) | 2001-09-10 | 2004-03-18 | Hua Yu | Stat3 agonists and antagonists and therapeutic uses thereof |
| JP2004524023A (ja) * | 2000-12-29 | 2004-08-12 | バイオ テクノロジー ジェネラル コーポレイション | 選択的癌療法のための特異的ヒト抗体 |
| AU2003219277A1 (en) * | 2002-03-14 | 2003-09-29 | Medical Research Council | Intracellular antibodies |
| GB0226727D0 (en) * | 2002-11-15 | 2002-12-24 | Medical Res Council | Intrabodies |
| CA2504818C (en) * | 2002-11-07 | 2013-04-23 | Immunogen, Inc. | Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same |
| NZ540196A (en) | 2002-11-08 | 2008-09-26 | Ablynx Nv | Camelidae antibodies against imminoglobulin E and use thereof for the treatment of allergic disorders |
| US20060034845A1 (en) | 2002-11-08 | 2006-02-16 | Karen Silence | Single domain antibodies directed against tumor necrosis factor alpha and uses therefor |
| EP1558646A2 (en) * | 2002-11-08 | 2005-08-03 | Ablynx N.V. | Single domain antibodies directed against interferon- gamma and uses thereof |
| GB0226729D0 (en) | 2002-11-15 | 2002-12-24 | Medical Res Council | Intracellular antibodies |
| US7638122B2 (en) | 2003-03-07 | 2009-12-29 | University Of South Florida | Stat3 antagonists and their use as vaccines against cancer |
| US20050226863A1 (en) | 2003-11-20 | 2005-10-13 | Massachusetts Institute Of Technology | Single-domain antibodies and uses thereof |
| US8188223B2 (en) | 2005-05-18 | 2012-05-29 | Ablynx N.V. | Serum albumin binding proteins |
| DE102005023617A1 (de) | 2005-05-21 | 2006-11-23 | Aspre Ag | Verfahren zum Mischen von Farben in einem Display |
| WO2008070363A2 (en) | 2006-10-31 | 2008-06-12 | Domantis Limited | Intrabodies |
| CA2588106A1 (en) * | 2007-05-18 | 2008-11-18 | Nrc - Institute For Biological Sciences | Single-domain antibodies and heavy chain antibody against egfr and uses thereof |
| EP2008666A1 (en) | 2007-06-29 | 2008-12-31 | Institut Pasteur | Use of VHH antibodies for the preparation of peptide vectors for delivering a substance of interest and their applications |
| WO2009033091A1 (en) * | 2007-09-06 | 2009-03-12 | City Of Hope | Treatment of th17-mediated autoimmune disease via inhibition of stat3 |
| BRPI0910198A2 (pt) * | 2008-06-30 | 2016-01-12 | Silenseed Ltd | composição para administração a partir de um sítio local de um agente baseado em nucleotídeos e método para tratar um sujeito sofrendo de uma doença requerendo tratamento local com um agente baseado em nucleotídeo. |
| EP2143735A1 (en) | 2008-07-10 | 2010-01-13 | Institut Pasteur | Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins |
| US20100092470A1 (en) * | 2008-09-22 | 2010-04-15 | Icb International, Inc. | Antibodies, analogs and uses thereof |
| WO2011051327A2 (en) | 2009-10-30 | 2011-05-05 | Novartis Ag | Small antibody-like single chain proteins |
| US20130177979A1 (en) | 2010-06-22 | 2013-07-11 | University Of Central Florida Research Foundation, Inc. | Methods and compositions for cell permeable stat3 inhibitor |
| US9879093B2 (en) * | 2011-12-20 | 2018-01-30 | Adaerata, Limited Partnershp | Single domain antibodies as inhibitors of PCSK9 |
| EP2920308B1 (en) * | 2012-10-31 | 2018-12-12 | Ionis Pharmaceuticals, Inc. | Cancer treatment |
| WO2014144148A1 (en) * | 2013-03-15 | 2014-09-18 | Dana-Farber Cancer Institute, Inc. | Stabilized sos1 peptides |
| US9802888B2 (en) * | 2013-03-22 | 2017-10-31 | University Of Hawaii | STAT3 inhibitors |
| CN103368197B (zh) | 2013-07-15 | 2015-11-25 | 国家电网公司 | 模块化多电平换流器的阀基控制设备和方法 |
| JP6736464B2 (ja) | 2013-08-29 | 2020-08-05 | シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ | 細胞透過性コンジュゲート及びその使用の方法 |
| EP2873680A1 (en) | 2013-11-13 | 2015-05-20 | F.Hoffmann-La Roche Ag | Oligopeptide and methods for producing conjugates thereof |
| EP2899208A1 (en) | 2014-01-28 | 2015-07-29 | F.Hoffmann-La Roche Ag | Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof |
| DK3590962T3 (da) | 2014-10-23 | 2021-12-13 | Singh Molecular Medicine Llc | Enkeltdomæneantistoffer rettet mod intracellulære antigener |
-
2015
- 2015-10-23 DK DK19165430.0T patent/DK3590962T3/da active
- 2015-10-23 CA CA2962275A patent/CA2962275C/en active Active
- 2015-10-23 KR KR1020197026711A patent/KR102207382B1/ko active Active
- 2015-10-23 WO PCT/US2015/057223 patent/WO2016065323A2/en not_active Ceased
- 2015-10-23 HR HRP20211889TT patent/HRP20211889T1/hr unknown
- 2015-10-23 SM SM20190413T patent/SMT201900413T1/it unknown
- 2015-10-23 EP EP21192390.9A patent/EP4006052A1/en active Pending
- 2015-10-23 MX MX2017003268A patent/MX379450B/es unknown
- 2015-10-23 BR BR122020006907A patent/BR122020006907B8/pt active IP Right Grant
- 2015-10-23 RU RU2017116710A patent/RU2017116710A/ru not_active Application Discontinuation
- 2015-10-23 LT LTEP19165430.0T patent/LT3590962T/lt unknown
- 2015-10-23 US US14/922,098 patent/US9663570B2/en active Active
- 2015-10-23 HU HUE19165430A patent/HUE057605T2/hu unknown
- 2015-10-23 BR BR122020006914A patent/BR122020006914B8/pt active IP Right Grant
- 2015-10-23 KR KR1020197026708A patent/KR102207381B1/ko active Active
- 2015-10-23 SM SM20210695T patent/SMT202100695T1/it unknown
- 2015-10-23 BR BR112017008165A patent/BR112017008165B8/pt active IP Right Grant
- 2015-10-23 DK DK15853465.1T patent/DK3209685T3/da active
- 2015-10-23 RS RS20190750A patent/RS59063B1/sr unknown
- 2015-10-23 LT LTEP15853465.1T patent/LT3209685T/lt unknown
- 2015-10-23 EP EP15853465.1A patent/EP3209685B1/en active Active
- 2015-10-23 KR KR1020187004337A patent/KR102023289B1/ko active Active
- 2015-10-23 KR KR1020177006630A patent/KR101831123B1/ko active Active
- 2015-10-23 ES ES15853465T patent/ES2731876T3/es active Active
- 2015-10-23 ES ES19165430T patent/ES2900253T3/es active Active
- 2015-10-23 SI SI201531763T patent/SI3590962T1/sl unknown
- 2015-10-23 AU AU2015335600A patent/AU2015335600B2/en active Active
- 2015-10-23 RS RS20211519A patent/RS62694B1/sr unknown
- 2015-10-23 US US14/922,100 patent/US9546211B2/en active Active
- 2015-10-23 HU HUE15853465A patent/HUE047601T2/hu unknown
- 2015-10-23 CA CA3052777A patent/CA3052777C/en active Active
- 2015-10-23 IL IL289769A patent/IL289769B2/en unknown
- 2015-10-23 TW TW104134979A patent/TWI664289B/zh active
- 2015-10-23 JP JP2017521577A patent/JP2017538671A/ja active Pending
- 2015-10-23 CN CN202010738353.7A patent/CN111848793B/zh not_active Expired - Fee Related
- 2015-10-23 HR HRP20191056TT patent/HRP20191056T1/hr unknown
- 2015-10-23 PT PT15853465T patent/PT3209685T/pt unknown
- 2015-10-23 PT PT191654300T patent/PT3590962T/pt unknown
- 2015-10-23 CA CA3114318A patent/CA3114318A1/en active Pending
- 2015-10-23 PL PL15853465T patent/PL3209685T3/pl unknown
- 2015-10-23 US US14/922,093 patent/US9695234B2/en active Active
- 2015-10-23 PL PL19165430T patent/PL3590962T3/pl unknown
- 2015-10-23 SI SI201530789T patent/SI3209685T1/sl unknown
- 2015-10-23 US US14/922,081 patent/US20160115247A1/en not_active Abandoned
- 2015-10-23 CN CN201580056968.9A patent/CN106852148B/zh active Active
- 2015-10-23 BR BR122020006918A patent/BR122020006918B8/pt active IP Right Grant
- 2015-10-23 EP EP19165430.0A patent/EP3590962B1/en active Active
-
2017
- 2017-03-06 IL IL250961A patent/IL250961B/en unknown
- 2017-03-10 MX MX2021001098A patent/MX2021001098A/es unknown
-
2019
- 2019-03-28 JP JP2019062231A patent/JP6670963B2/ja active Active
- 2019-06-28 AU AU2019204614A patent/AU2019204614B2/en not_active Ceased
- 2019-07-03 CY CY20191100706T patent/CY1122035T1/el unknown
- 2019-08-16 JP JP2019149269A patent/JP6928773B2/ja active Active
-
2021
- 2021-01-22 AU AU2021200416A patent/AU2021200416B2/en active Active
- 2021-06-25 JP JP2021105631A patent/JP6986180B2/ja active Active
- 2021-11-26 JP JP2021192139A patent/JP7195400B2/ja active Active
- 2021-12-09 CY CY20211101082T patent/CY1124867T1/el unknown
-
2022
- 2022-06-15 AU AU2022204167A patent/AU2022204167A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017538671A5 (OSRAM) | ||
| RU2017116710A (ru) | Однодоменные антитела, направленные против внутриклеточных антигенов | |
| Zhuang et al. | IL-6 induced lncRNA MALAT1 enhances TNF-α expression in LPS-induced septic cardiomyocytes via activation of SAA3. | |
| Hong et al. | Hepatic stellate cells express functional CXCR4: Role in stromal cell–derived factor‐1α–mediated stellate cell activation | |
| Deng et al. | STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib | |
| US20210024893A1 (en) | Medical uses of exosomes | |
| Saeedi-Boroujeni et al. | Tranilast: a potential anti-Inflammatory and NLRP3 inflammasome inhibitor drug for COVID-19 | |
| Deng et al. | Targeting transmembrane BAX inhibitor motif containing 1 alleviates pathological cardiac hypertrophy | |
| JP2016530323A5 (OSRAM) | ||
| JP2015506944A5 (OSRAM) | ||
| Suzukawa et al. | Leptin enhances ICAM-1 expression, induces migration and cytokine synthesis, and prolongs survival of human airway epithelial cells | |
| EA201100641A1 (ru) | Антитела к il-6 и их применение | |
| Guo et al. | Glycyrrhizic acid alleviates liver fibrosis in vitro and in vivo via activating CUGBP1-mediated IFN-γ/STAT1/Smad7 pathway | |
| JP2019504107A5 (OSRAM) | ||
| EA201991704A2 (ru) | Моноклональные антитела против ингибитора пути тканевого фактора (tfpi) | |
| EP3120142A2 (en) | Use of compounds inhibiting apelin / apj / gp130 signaling for treating cancer | |
| JP2021181450A (ja) | 細胞内抗原に対して向けられた単一ドメイン抗体 | |
| BR112015001102A2 (pt) | método de detecção de câncer, droga ou kit e método de seleção de droga terapêutica | |
| Nkongolo et al. | The retinoic acid receptor (RAR) α-specific agonist Am80 (tamibarotene) and other RAR agonists potently inhibit hepatitis B virus transcription from cccDNA | |
| Justinich et al. | The extracellular calcium-sensing receptor (CaSR) on human esophagus and evidence of expression of the CaSR on the esophageal epithelial cell line (HET-1A) | |
| Fraisier et al. | Hepatocyte pathway alterations in response to in vitro Crimean Congo hemorrhagic fever virus infection | |
| Kim et al. | xCT-mediated glutamate excretion in white adipocytes stimulates interferon-γ production by natural killer cells in obesity | |
| JP2012521549A5 (OSRAM) | ||
| Fetissov et al. | Immunoglobulin G preparation from plasma samples and analysis of its affinity kinetic binding to peptide hormones | |
| US20240325437A1 (en) | Methods and compositions for use in improving adaptive immunity in the elderly population |